LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

Cipher Pharmaceuticals Schedules Q2 2025 Earnings Release and Conference Call

July 29, 2025 | Last Trade: C$14.94 0.11 -0.73

MISSISSAUGA, ON, July 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The Company will also hold a conference call on Friday, August 8, 2025 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS

DATE:

                  Friday, August 8, 2025

TIME:

                  8:30 a.m. ET

DIAL-IN NUMBER:

                  416-945-7677 or 888-699-1199

REPLAY:

                  289-819-1450 or 888-660-6345 Code: 36094#

 

                  Expires: August 15, 2025

WEBCAST:

                  https://app.webinar.net/2vQrZ2AYmV5

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

Chimerix

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page